CLINICAL_TRIALS ClinicalTrials.gov record update

Phase II Study of Bevacizumab Plus Irinotecan (Camptosar™) in Children With Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT00381797
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:36:44.411984+00:00
Published At: 2013-01-15T00:00:00+00:00
Record Updated At: 2017-11-28
Results Posted At: 2013-01-15
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Childhood Cerebral Anaplastic Astrocytoma", "Childhood Oligodendroglioma", "Childhood Spinal Cord Neoplasm", "Recurrent Childhood Brain Stem Glioma", "Recurrent Childhood Ependymoma", "Recurrent Childhood Medulloblastoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2017-11-28"
protocolSection.identificationModule.nctId: "NCT00381797"
protocolSection.identificationModule.officialTitle: "Phase II Study of Bevacizumab Plus Irinotecan (Camptosar\u2122) in Children With Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2013-01-15"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.